Fakhkhari Meryem, Caidi Hayat, Sadki Khalid
Research Laboratory in Oral Biology and Biotechnology, Faculty of Dental Medicine, Mohammed V University in Rabat, Rabat, Morocco.
NARST Surveillance Unit, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA USA.
Egypt J Med Hum Genet. 2023;24(1):10. doi: 10.1186/s43042-023-00390-5. Epub 2023 Jan 22.
COVID-19 is a respiratory disease caused by a novel coronavirus called as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Detected for the first time in December 2019 in Wuhan and it has quickly spread all over the world in a couple of months and becoming a world pandemic. Symptoms of the disease and clinical outcomes are very different in infected people. These differences highlight the paramount need to study and understand the human genetic variation that occurring viral infections. Human leukocyte antigen (HLA) is an important component of the viral antigen presentation pathway, and it plays an essential role in conferring differential viral susceptibility and severity of diseases. HLA alleles have been involved in the immune response to viral diseases such as SARS-CoV-2.
Herein, we sought to evaluate this hypothesis by summarizing the association between HLA class I and class II alleles with COVID-19 susceptibility and/or severity reported in previous studies among different populations (Chinese, Italian, Iranian, Japanese, Spanish, etc.). The findings of all selected articles showed that several alleles have been found associated with COVID-19 susceptibility and severity. Even results across articles have been inconsistent and, in some cases, conflicting, highlighting that the association between the HLA system and the COVID-19 outcome might be ethnic-dependent, there were some alleles in common between some populations such as HLA-DRB115 and HLA-A30:02.
These contradictory findings warrant further large, and reproducible studies to decipher any possible genetic predisposition underlying susceptibility to SARS-COV-2 and disease progression and host immune response.
新型冠状病毒肺炎(COVID-19)是一种由名为严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的新型冠状病毒引起的呼吸道疾病。2019年12月在武汉首次被发现,在几个月内迅速蔓延至全球,成为一场全球大流行疾病。该疾病在感染者中的症状和临床结果差异很大。这些差异凸显了研究和了解病毒感染时人类基因变异的迫切需求。人类白细胞抗原(HLA)是病毒抗原呈递途径的重要组成部分,在赋予不同的病毒易感性和疾病严重程度方面起着至关重要的作用。HLA等位基因参与了对诸如SARS-CoV-2等病毒性疾病的免疫反应。
在此,我们试图通过总结先前在不同人群(中国、意大利、伊朗、日本、西班牙等)的研究中报道的HLA I类和II类等位基因与COVID-19易感性和/或严重程度之间的关联来评估这一假设。所有选定文章的研究结果表明,已发现多个等位基因与COVID-19易感性和严重程度相关。即使各文章的结果也不一致,在某些情况下甚至相互矛盾,这突出表明HLA系统与COVID-19结果之间的关联可能因种族而异,一些人群之间存在一些共同的等位基因,如HLA-DRB115和HLA-A30:02。
这些相互矛盾的研究结果需要进一步开展大规模、可重复的研究,以解读SARS-CoV-2易感性、疾病进展和宿主免疫反应背后任何可能的遗传易感性。